According to the Zhitong Finance APP report, sinopharm tech (08156) announced that all the prerequisites under the IAM loan capitalisation agreement and Quantum loan capitalisation agreement have been met, and the completion will occur on November 15, 2024.

Upon the completion of the IAM loan capitalisation agreement, 0.3 billion shares of IAM will be allotted and issued to IAM at a price of 0.1 Hong Kong dollars per ordinary share, with the subscription price offsetting 30 million Hong Kong dollars of IAM debt; 0.933 billion shares of IAM convertible preferred shares will be allotted and issued to IAM at a price of 0.1 Hong Kong dollars per share, with the subscription price offsetting approximately 93.2541 million Hong Kong dollars of IAM debt balance. After the completion of the IAM loan capitalisation agreement, IAM debt has been fully repaid, and the company has been released from its obligations under the IAM debt.

Upon the completion of the Quantum loan capitalisation agreement, 0.15 billion shares of Quantum will be allotted and issued to Quantum at a price of 0.1 Hong Kong dollars per ordinary share, with the subscription price offsetting the full amount of Quantum debt. After the completion of the Quantum loan capitalisation agreement, Quantum debt has been fully repaid, and the company has been released from its obligations under the Quantum debt.

All prerequisites under the Creative Big loan capitalisation agreement have been met, and completion will occur on November 15, 2024.

Upon the completion of the Creative Big loan capitalisation agreement, 0.548 billion shares of Creative Big convertible preferred shares will be allotted and issued to Creative Big at a price of 0.1 Hong Kong dollars per convertibles, with the subscription price offsetting the full amount of Creative Big debt. After the completion of the Creative Big loan capitalisation agreement, Creative Big debt has been fully repaid, and the company has been released from its obligations under the Creative Big debt.